• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

磷酸化蛋白质组学筛选鉴定黑色素瘤中的潜在治疗靶点。

Phosphoproteomic screen identifies potential therapeutic targets in melanoma.

机构信息

Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.

出版信息

Mol Cancer Res. 2011 Jun;9(6):801-12. doi: 10.1158/1541-7786.MCR-10-0512. Epub 2011 Apr 26.

DOI:10.1158/1541-7786.MCR-10-0512
PMID:21521745
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3117976/
Abstract

Therapies directed against receptor tyrosine kinases are effective in many cancer subtypes, including lung and breast cancer. We used a phosphoproteomic platform to identify active receptor tyrosine kinases that might represent therapeutic targets in a panel of 25 melanoma cell strains. We detected activated receptors including TYRO3, AXL, MERTK, EPHB2, MET, IGF1R, EGFR, KIT, HER3, and HER4. Statistical analysis of receptor tyrosine kinase activation as well as ligand and receptor expression indicates that some receptors, such as FGFR3, may be activated via autocrine circuits. Short hairpin RNA knockdown targeting three of the active kinases identified in the screen, AXL, HER3, and IGF1R, inhibited the proliferation of melanoma cells and knockdown of active AXL also reduced melanoma cell migration. The changes in cellular phenotype observed on AXL knockdown seem to be modulated via the STAT3 signaling pathway, whereas the IGF1R-dependent alterations seem to be regulated by the AKT signaling pathway. Ultimately, this study identifies several novel targets for therapeutic intervention in melanoma.

摘要

针对受体酪氨酸激酶的治疗方法在许多癌症亚型中都有效,包括肺癌和乳腺癌。我们使用磷酸化蛋白质组学平台来鉴定 25 种黑素瘤细胞系中的活跃受体酪氨酸激酶,这些激酶可能成为治疗靶点。我们检测到激活的受体包括 TYRO3、AXL、MERTK、EPHB2、MET、IGF1R、EGFR、KIT、HER3 和 HER4。受体酪氨酸激酶激活以及配体和受体表达的统计分析表明,某些受体(如 FGFR3)可能通过自分泌回路激活。针对筛选中鉴定出的三种活跃激酶(AXL、HER3 和 IGF1R)的短发夹 RNA 敲低抑制了黑素瘤细胞的增殖,而活跃 AXL 的敲低也降低了黑素瘤细胞的迁移。AXL 敲低观察到的细胞表型变化似乎通过 STAT3 信号通路进行调节,而 IGF1R 依赖性改变似乎受 AKT 信号通路调节。最终,这项研究确定了几种新的黑素瘤治疗干预靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e9/3117976/b47be8bf5047/nihms290604f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e9/3117976/45d6284dff1c/nihms290604f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e9/3117976/bb33c25e5423/nihms290604f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e9/3117976/591fddfb1641/nihms290604f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e9/3117976/b47be8bf5047/nihms290604f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e9/3117976/45d6284dff1c/nihms290604f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e9/3117976/bb33c25e5423/nihms290604f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e9/3117976/591fddfb1641/nihms290604f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e9/3117976/b47be8bf5047/nihms290604f4.jpg

相似文献

1
Phosphoproteomic screen identifies potential therapeutic targets in melanoma.磷酸化蛋白质组学筛选鉴定黑色素瘤中的潜在治疗靶点。
Mol Cancer Res. 2011 Jun;9(6):801-12. doi: 10.1158/1541-7786.MCR-10-0512. Epub 2011 Apr 26.
2
MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL.MERTK 控制黑色素瘤细胞的迁移和存活,并相对于 AXL 差异化调节细胞行为。
Pigment Cell Melanoma Res. 2013 Jul;26(4):527-41. doi: 10.1111/pcmr.12110. Epub 2013 May 21.
3
MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.MET 和 AXL 抑制剂 NPS-1034 对由于 MET 或 AXL 激活而对 EGFR 激酶抑制剂产生抗性的肺癌细胞具有疗效。
Cancer Res. 2014 Jan 1;74(1):253-62. doi: 10.1158/0008-5472.CAN-13-1103. Epub 2013 Oct 28.
4
The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.受体 AXL 使 EGFR 信号多样化,并限制三阴性乳腺癌细胞对 EGFR 靶向抑制剂的反应。
Sci Signal. 2013 Aug 6;6(287):ra66. doi: 10.1126/scisignal.2004155.
5
Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.磷酸化蛋白质组学分析间变性淋巴瘤激酶(ALK)下游信号通路发现信号转导子和转录激活子 3 是神经母细胞瘤细胞中激活的 ALK 的功能靶标。
FEBS J. 2013 Nov;280(21):5269-82. doi: 10.1111/febs.12453. Epub 2013 Aug 22.
6
Knockdown Suppresses the Growth of Myeloid Leukaemia Cells.敲低抑制髓系白血病细胞的生长。
Anticancer Res. 2022 Apr;42(4):1757-1761. doi: 10.21873/anticanres.15652.
7
Activated tyrosine kinases in gastrointestinal stromal tumor with loss of KIT oncoprotein expression.胃肠道间质瘤中失去 KIT 癌蛋白表达的激活酪氨酸激酶。
Cell Cycle. 2018;17(23):2577-2592. doi: 10.1080/15384101.2018.1553335. Epub 2018 Dec 4.
8
Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.联合抑制AXL、Lyn和p130Cas激酶可阻断三阴性乳腺癌细胞的迁移。
Cancer Biol Ther. 2014;15(11):1571-82. doi: 10.4161/15384047.2014.956634.
9
Galectin-3 Stimulates Tyro3 Receptor Tyrosine Kinase and Erk Signalling, Cell Survival and Migration in Human Cancer Cells.半乳糖凝集素-3 可刺激酪氨酸 3 受体酪氨酸激酶和 Erk 信号转导、细胞存活和人类癌细胞迁移。
Biomolecules. 2020 Jul 11;10(7):1035. doi: 10.3390/biom10071035.
10
AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.AXL 降解与 EGFR-TKI 联合使用可延缓并克服人类非小细胞肺癌细胞获得性耐药。
Cell Death Dis. 2019 May 1;10(5):361. doi: 10.1038/s41419-019-1601-6.

引用本文的文献

1
Association of Personal Care and Consumer Product Chemicals with Long-Term Amenorrhea: Insights into Serum Globulin and STAT3.个人护理及消费品化学品与长期闭经的关联:血清球蛋白和信号转导与转录激活因子3的相关见解
Toxics. 2025 Mar 5;13(3):187. doi: 10.3390/toxics13030187.
2
Revealing the role of RAB27 in HER receptor family expression and signaling in melanoma cells.揭示RAB27在黑色素瘤细胞中HER受体家族表达及信号传导中的作用。
Cell Commun Signal. 2025 Mar 4;23(1):118. doi: 10.1186/s12964-025-02064-8.
3
Combinations of EGFR and MET inhibitors reduce proliferation and invasiveness of mucosal melanoma cells.表皮生长因子受体(EGFR)和间质上皮转化因子(MET)抑制剂的联合使用可降低黏膜黑色素瘤细胞的增殖和侵袭能力。
J Cell Mol Med. 2023 Oct;27(19):2995-3008. doi: 10.1111/jcmm.17935. Epub 2023 Sep 7.
4
Tumor Microenvironment as a Therapeutic Target in Melanoma Treatment.肿瘤微环境作为黑色素瘤治疗的一个治疗靶点。
Cancers (Basel). 2023 Jun 11;15(12):3147. doi: 10.3390/cancers15123147.
5
An estrogen response-related signature predicts response to immunotherapy in melanoma.雌激素反应相关特征可预测黑色素瘤对免疫治疗的反应。
Front Immunol. 2023 May 12;14:1109300. doi: 10.3389/fimmu.2023.1109300. eCollection 2023.
6
Axl contributes to efficient migration and invasion of melanoma cells.Axl 有助于黑色素瘤细胞的有效迁移和侵袭。
PLoS One. 2023 Mar 29;18(3):e0283749. doi: 10.1371/journal.pone.0283749. eCollection 2023.
7
Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8 T Cells.MERTK和FLT3的小分子抑制剂可诱导人CD8 T细胞发生细胞周期阻滞。
Vaccines (Basel). 2021 Nov 8;9(11):1294. doi: 10.3390/vaccines9111294.
8
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma.IGF1R/IR介导BRAF突变型黑色素瘤对BRAF和MEK抑制剂的耐药性。
Cancers (Basel). 2021 Nov 22;13(22):5863. doi: 10.3390/cancers13225863.
9
RIPK3 and AXL Expression Study in Primary Cutaneous Melanoma Unmasks AXL as Predictor of Sentinel Node Metastasis: A Pilot Study.原发性皮肤黑色素瘤中RIPK3和AXL表达研究揭示AXL可作为前哨淋巴结转移的预测指标:一项初步研究
Front Oncol. 2021 Oct 21;11:728319. doi: 10.3389/fonc.2021.728319. eCollection 2021.
10
Aloysia Citrodora Essential Oil Inhibits Melanoma Cell Growth and Migration by Targeting HB-EGF-EGFR Signaling.柠檬香桃木精油通过靶向 HB-EGF-EGFR 信号抑制黑素瘤细胞生长和迁移。
Int J Mol Sci. 2021 Jul 29;22(15):8151. doi: 10.3390/ijms22158151.

本文引用的文献

1
Receptor tyrosine kinases and their activation in melanoma.受体酪氨酸激酶及其在黑色素瘤中的激活。
Pigment Cell Melanoma Res. 2011 Jun;24(3):446-61. doi: 10.1111/j.1755-148X.2011.00836.x. Epub 2011 Mar 3.
2
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.黑色素瘤通过 RTK 或 N-RAS 上调获得对 B-RAF(V600E)抑制的耐药性。
Nature. 2010 Dec 16;468(7326):973-7. doi: 10.1038/nature09626. Epub 2010 Nov 24.
3
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.COT 通过激活 MAP 激酶通路驱动 RAF 抑制耐药。
Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627. Epub 2010 Nov 24.
4
Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.抑制 IGF1R 活性可增强曲妥珠单抗在 HER-2 阳性乳腺癌细胞中的应答。
Ann Oncol. 2011 Jan;22(1):68-73. doi: 10.1093/annonc/mdq349. Epub 2010 Jul 20.
5
Cell signaling by receptor tyrosine kinases.受体酪氨酸激酶的细胞信号转导。
Cell. 2010 Jun 25;141(7):1117-34. doi: 10.1016/j.cell.2010.06.011.
6
A growing family: adding mutated Erbb4 as a novel cancer target.不断壮大的家族:新增突变型 Erbb4 作为一种新的癌症靶标。
Cell Cycle. 2010 Apr 15;9(8):1487-503. doi: 10.4161/cc.9.8.11239.
7
Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma.特异性小分子酪氨酸激酶抑制剂 SU11274 抑制 c-Met 可降低实验性人黑色素瘤的生长和转移形成。
Curr Cancer Drug Targets. 2010 May;10(3):332-42. doi: 10.2174/156800910791190184.
8
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.PLX4032,一种选择性 BRAF(V600E) 激酶抑制剂,激活 ERK 通路,增强 BRAF 黑色素瘤细胞的迁移和增殖。
Pigment Cell Melanoma Res. 2010 Apr;23(2):190-200. doi: 10.1111/j.1755-148X.2010.00685.x. Epub 2010 Feb 10.
9
Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.非小细胞肺癌细胞对 MET 激酶抑制的获得性耐药是由向表皮生长因子受体依赖性的转变介导的。
Cancer Res. 2010 Feb 15;70(4):1625-34. doi: 10.1158/0008-5472.CAN-09-3620. Epub 2010 Feb 2.
10
Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.乳腺癌细胞对赫赛汀耐药时表皮生长因子受体 erbB2、erbB3 和胰岛素样生长因子-i 受体的异三聚体化。
Cancer Res. 2010 Feb 1;70(3):1204-14. doi: 10.1158/0008-5472.CAN-09-3321. Epub 2010 Jan 26.